clarithromycin has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, H; Gan, L; Guo, E; Huang, J; Lu, Y; Sun, C; Thapa, N; Wang, B; Xia, M; Zhou, B | 1 |
| Antony, SJ | 1 |
2 other study(ies) available for clarithromycin and Ovarian Neoplasms
| Article | Year |
|---|---|
Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Clarithromycin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Ovarian Neoplasms; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2019 |
Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host.
Topics: Adult; Catheter-Related Infections; Ciprofloxacin; Clarithromycin; Cross Infection; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ovarian Neoplasms; Sepsis; Vascular Access Devices | 2015 |